PHASE I/II STUDY OF COMBINATION OF SORAFENIB, VORINOSTAT, AND BORTEZOMIB FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA WITH COMPLEX- OR POOR-RISK (MONOSOMY 5/7) CYTOGENETICS OR FLT3-ITD POSITIVE GENOTYPE: